Overview of Weihe year-end summary meeting
Release time:2021-02-05 10:56:00
"Riding the wind and breaking the waves sometimes, hanging a cloud sail to the vast sea"
2020 has passed in a blink of an eye, and 2021 has quietly arrived. On this occasion of bidding farewell to the old and welcoming the new, looking back on the past year of 2020, all employees of Weihe Biotechnology have withstood the pressure of the epidemic, overcome practical difficulties, consolidated the foundation of development, and steadily entered the new year.
Due to the limitations of the epidemic, a delicate venue was set up within the company for this year-end summary meeting, and a sumptuous meal was prepared, allowing every employee to enjoy a relaxed and happy time here.
A thousand mile trip begins with one step.
At the beginning of the summary meeting, the chairman gave a brief and concise speech, summarizing the company's experience and achievements over the year, and providing feedback on various aspects of the work.
Technical Research and Development Department: With a hundred feet of expertise, we have developed various new types of genetic testing reagents, undertaken all technical service orders and daily testing, and tested tens of thousands of samples throughout the year;
Product Registration Department: Adhere to regulations and actively complete product registration and application work. In 2020, I obtained one Class II medical device registration certificate and one EU CE registration certification, and completed the clinical and application work for two Class III products. I am waiting for the physical examination certificate to be issued. At the same time, I have applied for more than ten invention patents and participated in the formulation of a national standard. Three products have become designated reference materials for the country, and multiple new products have completed registration and inspection. The company's registered product philatelic growth is just around the corner.
The Marketing Department is determined to make progress and actively explore the market. In 2020, it has covered 90% of provincial-level blood centers in China, with some products having a market share of over 95%. The clinical connection and sample collection work is progressing in an orderly manner, laying the foundation for the explosive growth of sales in 2021. At the same time, actively exploring overseas markets and continuously striving to further achieve internationalization.
Production Quality Department: Step by step, we strictly control product quality, establish a complete quality production management system, and steadily progress in applying for ISO13485 quality management system certification. The warehouse management work is meticulous, and the logistics support work is orderly.
Human Resources and Finance Departments: Work meticulously, steadily, and effectively manage internal controls.
There is no perfect individual, only a perfect team. The development of Weihe is the result of the collaborative efforts of various departments and employees, and Weihe's development has also built a broader and higher platform for employees to share weal and woe!
In 2020, Weihe Biotechnology seized its own advantages, consolidated its product system, and resolutely reduced external environmental impacts, further accelerating its development speed and distinctive features. As the company gradually grows, many investors are also throwing olive branches. Weihe Biotechnology has signed a second round of investment agreements, and more resources and friends are the engine of the company's rapid development. The company will also become an effective platform for investment returns. With the support of the investor Jiu trillion capital, the company started 2021 with great enthusiasm by constructing a new 5000 square meter testing and administrative center in the sixth phase of China Pharmaceutical City (Taizhou), and is also promoting the landing of the temporary inspection center project in Yibin, Sichuan. We are full of hope and hope that in 2021, Weihe Biological's product system will be further improved, and its self-produced and self inspected business model will take shape. The "dual wheel drive" strategic plan will be able to operate effectively.
Although there are many walls of honor for the company, they are not yet full. In the future, Weihe will continue to strive and enrich itself, while also fulfilling our commitment to society, creating a new era of "Made in China" image, and driving the development of the domestic molecular diagnosis industry. Let's wait and see!
Now Location：Home--News Center--Company News
